Artiva Biotherapeutics (ARTV) Expected to Announce Earnings on Monday

Artiva Biotherapeutics (NASDAQ:ARTV) is anticipated to release its Q4 2025 results before the market opens on Monday, March 30th. Analysts expect Artiva Biotherapeutics to post earnings of ($0.87) per share for the quarter. Individuals can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Tuesday, March 10, 2026 at 7:00 AM ET.

Artiva Biotherapeutics (NASDAQ:ARTV) last announced its quarterly earnings results on Tuesday, March 10th. The company reported ($0.84) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.87) by $0.03. On average, analysts expect Artiva Biotherapeutics to post $-5 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Artiva Biotherapeutics Stock Performance

ARTV stock opened at $5.32 on Monday. The company has a market capitalization of $131.51 million, a P/E ratio of -1.56 and a beta of 2.12. The company has a fifty day moving average price of $4.90 and a 200-day moving average price of $4.08. Artiva Biotherapeutics has a 52-week low of $1.47 and a 52-week high of $7.75.

Institutional Investors Weigh In On Artiva Biotherapeutics

Several large investors have recently modified their holdings of the company. Prelude Capital Management LLC bought a new position in Artiva Biotherapeutics during the third quarter worth $41,000. Bank of America Corp DE grew its holdings in Artiva Biotherapeutics by 225.8% during the 3rd quarter. Bank of America Corp DE now owns 16,145 shares of the company’s stock worth $46,000 after acquiring an additional 11,190 shares during the period. OMERS ADMINISTRATION Corp acquired a new stake in Artiva Biotherapeutics during the 4th quarter worth about $91,000. Bridgeway Capital Management LLC bought a new position in shares of Artiva Biotherapeutics in the 2nd quarter worth about $53,000. Finally, Qube Research & Technologies Ltd bought a new position in shares of Artiva Biotherapeutics in the 2nd quarter worth about $58,000.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on ARTV. Weiss Ratings restated a “sell (d-)” rating on shares of Artiva Biotherapeutics in a report on Tuesday, January 27th. Needham & Company LLC reaffirmed a “buy” rating and set a $18.00 target price on shares of Artiva Biotherapeutics in a report on Wednesday, March 11th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $19.00.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.